S-488210 is a Subunit Vaccine owned by Shionogi &, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.
S-4884210 is a peptide vaccine. Upon administration of peptide vaccine, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.
The revenue for S-488210 is expected to reach a total of $154m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the S-488210 NPV Report.
S-488210 was originated by OncoTherapy Science and is currently owned by Shionogi &.
S-488210 is under development for the treatment of non-muscle invasive bladder cancer, recurrent and/or metastatic head and neck squamous cell carcinoma after failure of platinum based chemotherapy. It is administered through subcutaneous injection as powder for injection. S-488210 is a cancer peptide vaccine, which contains the three human leukocyte antigens (HLA) -restricted peptides up-regulated lung cancer 10, cell division cycle-associated protein 1 and insulin-like growth factor 2 mRNA-binding protein 3. It was also under development for the treatment of oral cancer, oropharyngeal cancer, laryngeal cancer and hypopharyngeal cancer
Shionogi & Overview
Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.
Quick View – S-488210
|Highest Development Stage|